Publication

Pharmacokinetics of clomipramine during pregnancy

Ter Horst, P. G. J., Proost, J. H., Smit, J. P., Vries, M. T., de Jong-van den Berg, L. & Wilffert, B., Dec-2015, In : European Journal of Clinical Pharmacology. 71, 12, p. 1493-1500 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Ter Horst, P. G. J., Proost, J. H., Smit, J. P., Vries, M. T., de Jong-van den Berg, L., & Wilffert, B. (2015). Pharmacokinetics of clomipramine during pregnancy. European Journal of Clinical Pharmacology, 71(12), 1493-1500. https://doi.org/10.1007/s00228-015-1944-6

Author

Ter Horst, P G J ; Proost, J H ; Smit, J P ; Vries, M T ; de Jong-van den Berg, Lolkje ; Wilffert, B. / Pharmacokinetics of clomipramine during pregnancy. In: European Journal of Clinical Pharmacology. 2015 ; Vol. 71, No. 12. pp. 1493-1500.

Harvard

Ter Horst, PGJ, Proost, JH, Smit, JP, Vries, MT, de Jong-van den Berg, L & Wilffert, B 2015, 'Pharmacokinetics of clomipramine during pregnancy', European Journal of Clinical Pharmacology, vol. 71, no. 12, pp. 1493-1500. https://doi.org/10.1007/s00228-015-1944-6

Standard

Pharmacokinetics of clomipramine during pregnancy. / Ter Horst, P G J; Proost, J H; Smit, J P; Vries, M T; de Jong-van den Berg, Lolkje; Wilffert, B.

In: European Journal of Clinical Pharmacology, Vol. 71, No. 12, 12.2015, p. 1493-1500.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Ter Horst PGJ, Proost JH, Smit JP, Vries MT, de Jong-van den Berg L, Wilffert B. Pharmacokinetics of clomipramine during pregnancy. European Journal of Clinical Pharmacology. 2015 Dec;71(12):1493-1500. https://doi.org/10.1007/s00228-015-1944-6


BibTeX

@article{fd3db5629ae74ea095650d149986be93,
title = "Pharmacokinetics of clomipramine during pregnancy",
abstract = "Clomipramine is one of the drugs for depression during pregnancy; however, pharmacokinetic data of clomipramine and its active metabolite desmethylclomipramine in this vulnerable period are lacking. In this study, we describe clomipramine and desmethylclomipramine concentrations including their ratios during pregnancy. Second, we describe Center for Epidemiologic Studies Depression scale (CES-D) scores during pregnancy.During 13 pregnancies, every trimester and 3 months after pregnancy, the clomipramine and desmethylclomipramine concentrations were measured with LC-MSMS and the severity of depression was assessed by taking the CES-D score. All concentrations used in our calculations were in fact the ratio between actual plasma concentration (mu g/l) and the actual dose (mg). We compared differences in ratios between trimesters by using the Friedman test.Studying 12 women and 13 pregnancies, we found no changes in mean clomipramine concentrations, a statistically significant decrease in mean desmethylclomipramine concentrations (p = 0.014) and a significant decrease in the ratio of desmethylclomipramine/clomipramine mean concentrations during pregnancy (p = 0.014) compared to the post-partum period. Sub-therapeutic concentrations of clomipramine and desmethylclomipramine were found in three patients during whole pregnancy.The mean concentrations of the pharmacologically active metabolite of clomipramine and desmethylclomipramine changes during pregnancy, where a decrease in mean concentrations was found during pregnancy. In case of recurrent disease, we recommend to control clomipramine and its metabolite concentrations, while both are active.",
keywords = "Clomipramine, Desmethylclomipramine, Pregnancy, DEPRESSION, PHARMACOGENETICS, PHARMACOMETRICS, ANTIDEPRESSANTS, GUIDELINES, SYMPTOMS, UPDATE",
author = "{Ter Horst}, {P G J} and Proost, {J H} and Smit, {J P} and Vries, {M T} and {de Jong-van den Berg}, Lolkje and B Wilffert",
year = "2015",
month = dec,
doi = "10.1007/s00228-015-1944-6",
language = "English",
volume = "71",
pages = "1493--1500",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "12",

}

RIS

TY - JOUR

T1 - Pharmacokinetics of clomipramine during pregnancy

AU - Ter Horst, P G J

AU - Proost, J H

AU - Smit, J P

AU - Vries, M T

AU - de Jong-van den Berg, Lolkje

AU - Wilffert, B

PY - 2015/12

Y1 - 2015/12

N2 - Clomipramine is one of the drugs for depression during pregnancy; however, pharmacokinetic data of clomipramine and its active metabolite desmethylclomipramine in this vulnerable period are lacking. In this study, we describe clomipramine and desmethylclomipramine concentrations including their ratios during pregnancy. Second, we describe Center for Epidemiologic Studies Depression scale (CES-D) scores during pregnancy.During 13 pregnancies, every trimester and 3 months after pregnancy, the clomipramine and desmethylclomipramine concentrations were measured with LC-MSMS and the severity of depression was assessed by taking the CES-D score. All concentrations used in our calculations were in fact the ratio between actual plasma concentration (mu g/l) and the actual dose (mg). We compared differences in ratios between trimesters by using the Friedman test.Studying 12 women and 13 pregnancies, we found no changes in mean clomipramine concentrations, a statistically significant decrease in mean desmethylclomipramine concentrations (p = 0.014) and a significant decrease in the ratio of desmethylclomipramine/clomipramine mean concentrations during pregnancy (p = 0.014) compared to the post-partum period. Sub-therapeutic concentrations of clomipramine and desmethylclomipramine were found in three patients during whole pregnancy.The mean concentrations of the pharmacologically active metabolite of clomipramine and desmethylclomipramine changes during pregnancy, where a decrease in mean concentrations was found during pregnancy. In case of recurrent disease, we recommend to control clomipramine and its metabolite concentrations, while both are active.

AB - Clomipramine is one of the drugs for depression during pregnancy; however, pharmacokinetic data of clomipramine and its active metabolite desmethylclomipramine in this vulnerable period are lacking. In this study, we describe clomipramine and desmethylclomipramine concentrations including their ratios during pregnancy. Second, we describe Center for Epidemiologic Studies Depression scale (CES-D) scores during pregnancy.During 13 pregnancies, every trimester and 3 months after pregnancy, the clomipramine and desmethylclomipramine concentrations were measured with LC-MSMS and the severity of depression was assessed by taking the CES-D score. All concentrations used in our calculations were in fact the ratio between actual plasma concentration (mu g/l) and the actual dose (mg). We compared differences in ratios between trimesters by using the Friedman test.Studying 12 women and 13 pregnancies, we found no changes in mean clomipramine concentrations, a statistically significant decrease in mean desmethylclomipramine concentrations (p = 0.014) and a significant decrease in the ratio of desmethylclomipramine/clomipramine mean concentrations during pregnancy (p = 0.014) compared to the post-partum period. Sub-therapeutic concentrations of clomipramine and desmethylclomipramine were found in three patients during whole pregnancy.The mean concentrations of the pharmacologically active metabolite of clomipramine and desmethylclomipramine changes during pregnancy, where a decrease in mean concentrations was found during pregnancy. In case of recurrent disease, we recommend to control clomipramine and its metabolite concentrations, while both are active.

KW - Clomipramine

KW - Desmethylclomipramine

KW - Pregnancy

KW - DEPRESSION

KW - PHARMACOGENETICS

KW - PHARMACOMETRICS

KW - ANTIDEPRESSANTS

KW - GUIDELINES

KW - SYMPTOMS

KW - UPDATE

U2 - 10.1007/s00228-015-1944-6

DO - 10.1007/s00228-015-1944-6

M3 - Article

C2 - 26416100

VL - 71

SP - 1493

EP - 1500

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 12

ER -

ID: 24341044